Date: 2015-08-17
Type of information: Nomination
Compound:
Company: ITeos Therapeutics (Belgium)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On August 17, 2015, ITeos Therapeutics announced the appointment of Christophe Quéva Ph.D., as the company\'s chief scientific officer. Dr. Quéva is a key addition to the scientific strength and direction for the company’s ambitions to expand its pipeline of immunomodulators for cancer therapies. Starting from his Ph.D. at the University of Lille, Dr. Quéva has pursued oncology, immunology and drug development, first with his postdoctoral studies at the Fred Hutchinson Cancer Research Center, followed by over 15 years of director level positions in oncology R&D at AstraZeneca, Amgen and Gilead Sciences. He has published numerous articles and patents in the field of cancer biology, immune therapy and drug discovery.
Financial terms:
Latest news:
